The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The company will soon be launching a new portfolio of products in this segment
Millions of stroke survivors across the world may soon have a new defense
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
